BioWorld

April 23, 2008

Resolvyx Adds $25M to Move First Resolvin Drugs into Clinic

Gearing up to move its first two drug candidates into the clinic this year, Resolvyx Pharmaceuticals Inc. padded its bank account with a $25 million Series B round from new and existing investors. (BioWorld Today) Read More

Congress Told Foreign Plants are 'Ticking Time Bombs'

'Pseudokinase' Found Active, Without Binding Magnesium

CuraGen Sells Cancer Drug to TopoTarget for $45M

Genzyme Must File 2 BLAs for Myozyme Formulations

Theravance Cuts Staff 40%; Telavancin Inches Along

FDA Approves Cimzia for Crohn's Disease

Spectrum Shares Falls on Ozarelix Miss

ImClone, BioVex Secure SPAs For Late-Stage Cancer Studies

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 14, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

NRF2 activators reported in Vailima Peninsula patent

BioWorld Science

Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026